



PRESS RELEASE  
FOR IMMEDIATE RELEASE

Media Contact:  
Meghan Brown  
T: 206/778-6218  
E: mbrown@epsilon-imaging.com

**STUDY DEMONSTRATES IMPROVED MONITORING OF PATIENTS AT RISK FOR  
CARDIOTOXICITY USING ECHOLNSIGHT® FOR CARDIO ONCOLOGY**

***Results Indicate Echolnsight® for Cardio Oncology is a High Quality, Efficient Application for  
Comprehensive Assessment and Serial Comparison of Left Ventricle (LV) Function***

***Company Showcasing Echolnsight and its Application Suite at the  
American Society of Echocardiography (ASE) 2013 Scientific Sessions***

Minneapolis, MN, July 1, 2013 – Epsilon Imaging, Inc., a visualization and analysis software provider transforming cardiac diagnostic workflow, today announced a study demonstrating Echolnsight for Cardio Oncology to be a high quality, efficient application for comprehensive assessment of LV function. The study, being presented at the ASE 2013 Scientific Sessions in Minneapolis, MN, further indicated Echolnsight for Cardio Oncology facilitates monitoring of patients at risk for cardiotoxicity. Echolnsight for Cardio Oncology is a vendor neutral application designed to assist clinicians in improving confidence and workflow of study interpretation and reporting when monitoring oncology patients. The Company is showcasing Echolnsight and its suite of applications at the conference (booth 522).

At ASE 2013, Jeanne DeCara, MD, et al. from the University of Chicago Medicine presented, "Vendor-Independent Software for Rapid Comprehensive Assessment of Changes in Left Ventricle Function During Serial Echocardiographic Studies." The study analyzed serial comparison studies from 30 subjects. Ejection fraction (EF) and longitudinal strain were measured to monitor change in cardiac function. An experienced reader reviewed the studies on another commercially available solution, and an inexperienced reader used Echolnsight for Cardio Oncology for analysis. The inexperienced reader also completed analysis without Echolnsight for Cardio Oncology. Study results concluded that analysis and interpretation is faster using Echolnsight for Cardio Oncology when compared to the other commercial application, and offers consistent findings. Echolnsight for Cardio Oncology also slightly improved the inexperienced reader's assessment of LV function change.

"Our study demonstrates Echolnsight for Cardio Oncology offers visualization and analysis that allows for quick, easy and accurate interpretation of LV function over time," said Dr. DeCara. "Echolnsight is a promising software application that may assist in the follow-up of patients undergoing potentially cardiotoxic treatments, such as chemotherapy."

**Understanding Cardiotoxicity and the Importance of Strain Imaging**

A study published in 2011 in the American Journal of Cardiology by Dr. Heloisa Sawaya and colleagues, concluded that longitudinal strain echocardiography, along with plasma concentrations of cardiac troponin, predicted the development of cardiotoxicity in patients treated with anthracyclines such as Doxorubicin and Trastuzumab. They noted that as breast-cancer survival increases, cardiotoxicity with the chemotherapeutic agents becomes a more significant issue, but the two parameters might be "useful to detect chemotherapy-treated patients who may benefit from alternative therapies, potentially decreasing the incidence of cardiotoxicity and its associated morbidity and mortality."



The ASE has indicated that guidelines to manage the risk of heart disease in cancer patients will soon be published to guide clinicians in the use of strain imaging with echocardiography for early detection of cardiotoxicity resulting from therapies used to treat cancer. Until now, strain imaging has been research-oriented, cumbersome to use and usually vendor specific.

### **Echolnsight for Cardio Oncology**

Echolnsight for Cardio Oncology allows clinicians to quickly and easily integrate strain imaging into the clinical environment, enabling improved patient management. Echolnsight for Cardio Oncology features include automated processing, rapid serial study comparison, and global and regional longitudinal strain and EF trending with percent change from baseline. The application also delivers detailed visual-based reporting to aid patient management and customized integration to customer healthcare IT workflow, along with premier remote customer support. Echolnsight for Cardio Oncology is now commercially available.

### **About Epsilon Imaging**

As a provider of workflow enhancing solutions for cardiology, Epsilon Imaging is transforming cardiac diagnostic workflow with a vendor neutral suite of software applications designed for echocardiography. Echolnsight provides a suite of clinical applications that provide visualization and analysis with practical strain imaging for the clinical environment. Applications assist clinicians to enhance, standardize, and streamline interpretation and reporting of echo studies. Initial applications include cardio oncology and stress echo. Learn more by visiting [epsilon-imaging.com](http://epsilon-imaging.com).

###